Holdings (Monthly)
Guide ↗
iShares Biotechnology ETF
· iShares Trust| # | Name | Ticker | Since | Shares | Value | % Port | Cat |
|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds III | 066922519 | Mar 2026 | 784,655,767 | $784.8M | 9.66% | STIV |
| 2 | Gilead Sciences, Inc. | 375558103 | Mar 2026 | 4,515,707 | $629.4M | 7.75% | EC |
| 3 | Amgen, Inc. | 031162100 | Mar 2026 | 1,733,148 | $609.8M | 7.51% | EC |
| 4 | Vertex Pharmaceuticals, Inc. | 92532F100 | Mar 2026 | 1,354,033 | $604.6M | 7.44% | EC |
| 5 | Regeneron Pharmaceuticals, Inc. | 75886F107 | Mar 2026 | 758,232 | $585.8M | 7.21% | EC |
| 6 | Alnylam Pharmaceuticals, Inc. | 02043Q107 | Mar 2026 | 979,642 | $324.1M | 3.99% | EC |
| 7 | Insmed, Inc. | 457669307 | Mar 2026 | 1,587,887 | $259.7M | 3.20% | EC |
| 8 | Argenx SE | 04016X101 | Mar 2026 | 341,883 | $249.7M | 3.07% | EC |
| 9 | Biogen, Inc. | 09062X103 | Mar 2026 | 1,091,046 | $200.0M | 2.46% | EC |
| 10 | Natera, Inc. | 632307104 | Mar 2026 | 980,622 | $196.1M | 2.41% | EC |
| 11 | United Therapeutics Corp. | 91307C102 | Mar 2026 | 315,509 | $187.1M | 2.30% | EC |
| 12 | BeOne Medicines Ltd. | 07725L102 | Mar 2026 | 529,143 | $157.1M | 1.93% | EC |
| 13 | Incyte Corp. | 45337C102 | Mar 2026 | 1,467,923 | $138.2M | 1.70% | EC |
| 14 | Moderna, Inc. | 60770K107 | Mar 2026 | 2,692,459 | $136.8M | 1.68% | EC |
| 15 | Illumina, Inc. | 452327109 | Mar 2026 | 1,107,291 | $136.5M | 1.68% | EC |
| 16 | Revolution Medicines, Inc. | 76155X100 | Mar 2026 | 1,283,912 | $124.9M | 1.54% | EC |
| 17 | Roivant Sciences Ltd. | N/A | Mar 2026 | 3,642,557 | $100.9M | 1.24% | EC |
| 18 | Neurocrine Biosciences, Inc. | 64125C109 | Mar 2026 | 727,502 | $95.8M | 1.18% | EC |
| 19 | Genmab A/S | 372303206 | Mar 2026 | 3,555,098 | $95.4M | 1.17% | EC |
| 20 | Bridgebio Pharma, Inc. | 10806X102 | Mar 2026 | 1,238,687 | $92.0M | 1.13% | EC |
| 21 | Ionis Pharmaceuticals, Inc. | 462222100 | Mar 2026 | 1,205,549 | $90.5M | 1.11% | EC |
| 22 | Medpace Holdings, Inc. | 58506Q109 | Mar 2026 | 169,922 | $81.6M | 1.00% | EC |
| 23 | Madrigal Pharmaceuticals, Inc. | 558868105 | Mar 2026 | 155,341 | $81.3M | 1.00% | EC |
| 24 | Exelixis, Inc. | 30161Q104 | Mar 2026 | 1,871,326 | $80.3M | 0.99% | EC |
| 25 | BioMarin Pharmaceutical, Inc. | 09061G101 | Mar 2026 | 1,412,330 | $79.8M | 0.98% | EC |
| 26 | Ascendis Pharma A/S | 04351P101 | Mar 2026 | 339,948 | $77.8M | 0.96% | EC |
| 27 | Praxis Precision Medicines, Inc. | 74006W207 | Mar 2026 | 195,097 | $62.9M | 0.77% | EC |
| 28 | Charles River Laboratories International, Inc. | 159864107 | Mar 2026 | 362,165 | $62.5M | 0.77% | EC |
| 29 | Arrowhead Pharmaceuticals, Inc. | 04280A100 | Mar 2026 | 975,175 | $61.1M | 0.75% | EC |
| 30 | Vaxcyte, Inc. | 92243G108 | Mar 2026 | 1,045,695 | $60.8M | 0.75% | EC |
| 31 | Bio-Techne Corp. | 09073M104 | Mar 2026 | 1,151,950 | $60.2M | 0.74% | EC |
| 32 | Cytokinetics, Inc. | 23282W605 | Mar 2026 | 896,972 | $59.1M | 0.73% | EC |
| 33 | Halozyme Therapeutics, Inc. | 40637H109 | Mar 2026 | 868,502 | $56.1M | 0.69% | EC |
| 34 | Axsome Therapeutics, Inc. | 05464T104 | Mar 2026 | 319,088 | $53.9M | 0.66% | EC |
| 35 | BioNTech SE | 09075V102 | Mar 2026 | 599,506 | $53.3M | 0.66% | EC |
| 36 | Krystal Biotech, Inc. | 501147102 | Mar 2026 | 188,966 | $48.8M | 0.60% | EC |
| 37 | Protagonist Therapeutics, Inc. | 74366E102 | Mar 2026 | 447,047 | $47.1M | 0.58% | EC |
| 38 | Repligen Corp. | 759916109 | Mar 2026 | 396,896 | $46.8M | 0.58% | EC |
| 39 | Kymera Therapeutics, Inc. | 501575104 | Mar 2026 | 521,385 | $43.4M | 0.53% | EC |
| 40 | Alkermes plc | N/A | Mar 2026 | 1,216,662 | $43.0M | 0.53% | EC |
| 41 | Rhythm Pharmaceuticals, Inc. | 76243J105 | Mar 2026 | 474,539 | $41.3M | 0.51% | EC |
| 42 | Abivax SA | 00370M103 | Mar 2026 | 367,461 | $40.9M | 0.50% | EC |
| 43 | PTC Therapeutics, Inc. | 69366J200 | Mar 2026 | 593,152 | $40.4M | 0.50% | EC |
| 44 | Cogent Biosciences, Inc. | 19240Q201 | Mar 2026 | 1,009,396 | $38.9M | 0.48% | EC |
| 45 | Arcellx, Inc. | 03940C100 | Mar 2026 | 335,814 | $38.6M | 0.47% | EC |
| 46 | Terns Pharmaceuticals, Inc. | 880881107 | Mar 2026 | 713,848 | $37.6M | 0.46% | EC |
| 47 | Nuvalent, Inc. | 670703107 | Mar 2026 | 355,481 | $36.4M | 0.45% | EC |
| 48 | Mirum Pharmaceuticals, Inc. | 604749101 | Mar 2026 | 392,677 | $36.3M | 0.45% | EC |
| 49 | Tempus AI, Inc. | 88023B103 | Mar 2026 | 773,906 | $35.0M | 0.43% | EC |
| 50 | Xenon Pharmaceuticals, Inc. | 98420N105 | Mar 2026 | 598,390 | $34.8M | 0.43% | EC |
| 51 | Amicus Therapeutics, Inc. | 03152W109 | Mar 2026 | 2,307,725 | $33.4M | 0.41% | EC |
| 52 | CRISPR Therapeutics AG | N/A | Mar 2026 | 663,733 | $31.6M | 0.39% | EC |
| 53 | Apellis Pharmaceuticals, Inc. | 03753U106 | Mar 2026 | 778,245 | $31.3M | 0.39% | EC |
| 54 | Apogee Therapeutics, Inc. | 03770N101 | Mar 2026 | 353,520 | $29.8M | 0.37% | EC |
| 55 | Scholar Rock Holding Corp. | 80706P103 | Mar 2026 | 593,730 | $29.2M | 0.36% | EC |
| 56 | ACADIA Pharmaceuticals, Inc. | 004225108 | Mar 2026 | 1,251,241 | $27.9M | 0.34% | EC |
| 57 | Bruker Corp. | 116794108 | Mar 2026 | 764,342 | $27.6M | 0.34% | EC |
| 58 | Crinetics Pharmaceuticals, Inc. | 22663K107 | Mar 2026 | 726,428 | $26.4M | 0.32% | EC |
| 59 | CG oncology, Inc. | 156944100 | Mar 2026 | 379,295 | $25.7M | 0.32% | EC |
| 60 | Spyre Therapeutics, Inc. | 00773J202 | Mar 2026 | 478,909 | $24.2M | 0.30% | EC |
| 61 | Erasca, Inc. | 29479A108 | Mar 2026 | 1,384,399 | $22.4M | 0.28% | EC |
| 62 | Tarsus Pharmaceuticals, Inc. | 87650L103 | Mar 2026 | 297,522 | $20.9M | 0.26% | EC |
| 63 | Twist Bioscience Corp. | 90184D100 | Mar 2026 | 436,795 | $20.8M | 0.26% | EC |
| 64 | Centessa Pharmaceuticals plc | 152309100 | Mar 2026 | 520,762 | $20.7M | 0.25% | EC |
| 65 | Ideaya Biosciences, Inc. | 45166A102 | Mar 2026 | 615,636 | $20.5M | 0.25% | EC |
| 66 | Denali Therapeutics, Inc. | 24823R105 | Mar 2026 | 1,055,210 | $20.3M | 0.25% | EC |
| 67 | Travere Therapeutics, Inc. | 89422G107 | Mar 2026 | 674,600 | $20.0M | 0.25% | EC |
| 68 | ImmunityBio, Inc. | 45256X103 | Mar 2026 | 2,572,701 | $19.7M | 0.24% | EC |
| 69 | Arcutis Biotherapeutics, Inc. | 03969K108 | Mar 2026 | 814,779 | $19.2M | 0.24% | EC |
| 70 | Veracyte, Inc. | 92337F107 | Mar 2026 | 579,343 | $18.7M | 0.23% | EC |
| 71 | Structure Therapeutics, Inc. | 86366E106 | Mar 2026 | 381,676 | $18.4M | 0.23% | EC |
| 72 | Edgewise Therapeutics, Inc. | 28036F105 | Mar 2026 | 572,192 | $18.0M | 0.22% | EC |
| 73 | 10X Genomics, Inc. | 88025U109 | Mar 2026 | 841,716 | $17.9M | 0.22% | EC |
| 74 | Legend Biotech Corp. | 52490G102 | Mar 2026 | 983,928 | $17.8M | 0.22% | EC |
| 75 | Newamsterdam Pharma Co. NV | N/A | Mar 2026 | 537,784 | $17.2M | 0.21% | EC |
| 76 | Vera Therapeutics, Inc. | 92337R101 | Mar 2026 | 419,778 | $16.9M | 0.21% | EC |
| 77 | Dyne Therapeutics, Inc. | 26818M108 | Mar 2026 | 917,470 | $16.6M | 0.20% | EC |
| 78 | Beam Therapeutics, Inc. | 07373V105 | Mar 2026 | 692,124 | $16.5M | 0.20% | EC |
| 79 | BioCryst Pharmaceuticals, Inc. | 09058V103 | Mar 2026 | 1,715,826 | $16.3M | 0.20% | EC |
| 80 | Kodiak Sciences, Inc. | 50015M109 | Mar 2026 | 422,431 | $16.1M | 0.20% | EC |
| 81 | Sarepta Therapeutics, Inc. | 803607100 | Mar 2026 | 739,607 | $16.1M | 0.20% | EC |
| 82 | Caris Life Sciences, Inc. | 142152107 | Mar 2026 | 898,011 | $16.1M | 0.20% | EC |
| 83 | Immunovant, Inc. | 45258J102 | Mar 2026 | 626,211 | $15.6M | 0.19% | EC |
| 84 | ADMA Biologics, Inc. | 000899104 | Mar 2026 | 1,711,239 | $15.4M | 0.19% | EC |
| 85 | Adaptive Biotechnologies Corp. | 00650F109 | Mar 2026 | 1,105,997 | $15.4M | 0.19% | EC |
| 86 | Summit Therapeutics, Inc. | 86627T108 | Mar 2026 | 799,477 | $15.2M | 0.19% | EC |
| 87 | Oruka Therapeutics, Inc. | 687604108 | Mar 2026 | 304,331 | $14.9M | 0.18% | EC |
| 88 | Syndax Pharmaceuticals, Inc. | 87164F105 | Mar 2026 | 631,524 | $14.8M | 0.18% | EC |
| 89 | Tango Therapeutics, Inc. | 87583X109 | Mar 2026 | 687,885 | $14.4M | 0.18% | EC |
| 90 | Ultragenyx Pharmaceutical, Inc. | 90400D108 | Mar 2026 | 680,286 | $14.3M | 0.18% | EC |
| 91 | Disc Medicine, Inc. | 254604101 | Mar 2026 | 214,889 | $13.7M | 0.17% | EC |
| 92 | Agios Pharmaceuticals, Inc. | 00847X104 | Mar 2026 | 400,087 | $13.5M | 0.17% | EC |
| 93 | GRAIL, Inc. | 384747101 | Mar 2026 | 261,045 | $13.5M | 0.17% | EC |
| 94 | Definium Therapeutics, Inc. | 24477V105 | Mar 2026 | 703,030 | $13.3M | 0.16% | EC |
| 95 | Zymeworks, Inc. | 98985Y108 | Mar 2026 | 529,981 | $13.3M | 0.16% | EC |
| 96 | Arcus Biosciences, Inc. | 03969F109 | Mar 2026 | 612,355 | $13.2M | 0.16% | EC |
| 97 | BlackRock Funds III | 066922477 | Mar 2026 | 12,996,156 | $13.0M | 0.16% | STIV |
| 98 | Aurinia Pharmaceuticals, Inc. | 05156V102 | Mar 2026 | 874,336 | $13.0M | 0.16% | EC |
| 99 | Enliven Therapeutics, Inc. | 29337E102 | Mar 2026 | 322,556 | $12.6M | 0.16% | EC |
| 100 | Day One Biopharmaceuticals, Inc. | 23954D109 | Mar 2026 | 578,773 | $12.4M | 0.15% | EC |
| 101 | Vericel Corp. | 92346J108 | Mar 2026 | 373,502 | $12.0M | 0.15% | EC |
| 102 | Mineralys Therapeutics, Inc. | 603170101 | Mar 2026 | 439,648 | $11.9M | 0.15% | EC |
| 103 | Alumis, Inc. | 022307102 | Mar 2026 | 530,358 | $11.7M | 0.14% | EC |
| 104 | Zai Lab Ltd. | 98887Q104 | Mar 2026 | 613,747 | $11.5M | 0.14% | EC |
| 105 | Nurix Therapeutics, Inc. | 67080M103 | Mar 2026 | 720,848 | $11.2M | 0.14% | EC |
| 106 | Stoke Therapeutics, Inc. | 86150R107 | Mar 2026 | 331,288 | $10.8M | 0.13% | EC |
| 107 | Intellia Therapeutics, Inc. | 45826J105 | Mar 2026 | 835,337 | $10.7M | 0.13% | EC |
| 108 | AnaptysBio, Inc. | 032724106 | Mar 2026 | 192,136 | $10.7M | 0.13% | EC |
| 109 | Recursion Pharmaceuticals, Inc. | 75629V104 | Mar 2026 | 3,419,857 | $10.5M | 0.13% | EC |
| 110 | Tyra Biosciences, Inc. | 90240B106 | Mar 2026 | 272,474 | $10.4M | 0.13% | EC |
| 111 | Relay Therapeutics, Inc. | 75943R102 | Mar 2026 | 980,266 | $9.8M | 0.12% | EC |
| 112 | Amylyx Pharmaceuticals, Inc. | 03237H101 | Mar 2026 | 687,536 | $9.6M | 0.12% | EC |
| 113 | Novavax, Inc. | 670002401 | Mar 2026 | 1,157,114 | $9.4M | 0.12% | EC |
| 114 | Iovance Biotherapeutics, Inc. | 462260100 | Mar 2026 | 2,619,021 | $9.2M | 0.11% | EC |
| 115 | WaVe Life Sciences Ltd. | N/A | Mar 2026 | 1,176,186 | $8.5M | 0.10% | EC |
| 116 | Immunocore Holdings plc | 45258D105 | Mar 2026 | 277,185 | $8.4M | 0.10% | EC |
| 117 | Novocure Ltd. | N/A | Mar 2026 | 763,201 | $8.3M | 0.10% | EC |
| 118 | Galapagos NV | 36315X101 | Mar 2026 | 271,893 | $8.2M | 0.10% | EC |
| 119 | Grifols SA | 398438408 | Mar 2026 | 976,161 | $7.8M | 0.10% | EC |
| 120 | Biohaven Ltd. | N/A | Mar 2026 | 917,535 | $7.8M | 0.10% | EC |
| 121 | Nuvation Bio, Inc. | 67080N101 | Mar 2026 | 1,795,888 | $7.7M | 0.09% | EC |
| 122 | AtaiBeckley, Inc. | 04650F101 | Mar 2026 | 2,160,067 | $7.6M | 0.09% | EC |
| 123 | Taysha Gene Therapies, Inc. | 877619106 | Mar 2026 | 1,672,180 | $7.5M | 0.09% | EC |
| 124 | Sionna Therapeutics, Inc. | 829401108 | Mar 2026 | 185,101 | $7.4M | 0.09% | EC |
| 125 | Trevi Therapeutics, Inc. | 89532M101 | Mar 2026 | 608,481 | $7.3M | 0.09% | EC |
| 126 | Mesoblast Ltd. | 590717401 | Mar 2026 | 460,143 | $7.1M | 0.09% | EC |
| 127 | Corvus Pharmaceuticals, Inc. | 221015100 | Mar 2026 | 473,326 | $6.9M | 0.09% | EC |
| 128 | Olema Pharmaceuticals, Inc. | 68062P106 | Mar 2026 | 457,751 | $6.8M | 0.08% | EC |
| 129 | Rapport Therapeutics, Inc. | 75383L102 | Mar 2026 | 217,759 | $6.8M | 0.08% | EC |
| 130 | uniQure NV | N/A | Mar 2026 | 413,699 | $6.8M | 0.08% | EC |
| 131 | Geron Corp. | 374163103 | Mar 2026 | 4,513,103 | $6.7M | 0.08% | EC |
| 132 | Fortrea Holdings, Inc. | 34965K107 | Mar 2026 | 693,057 | $6.5M | 0.08% | EC |
| 133 | Vir Biotechnology, Inc. | 92764N102 | Mar 2026 | 704,449 | $6.3M | 0.08% | EC |
| 134 | Xencor, Inc. | 98401F105 | Mar 2026 | 513,267 | $6.2M | 0.08% | EC |
| 135 | AbCellera Biologics, Inc. | 00288U106 | Mar 2026 | 1,732,022 | $6.0M | 0.07% | EC |
| 136 | MBX Biosciences, Inc. | 55287L101 | Mar 2026 | 199,599 | $6.0M | 0.07% | EC |
| 137 | Maze Therapeutics, Inc. | 578784100 | Mar 2026 | 197,936 | $5.9M | 0.07% | EC |
| 138 | CareDx, Inc. | 14167L103 | Mar 2026 | 337,886 | $5.9M | 0.07% | EC |
| 139 | Theravance Biopharma, Inc. | N/A | Mar 2026 | 353,652 | $5.7M | 0.07% | EC |
| 140 | Monte Rosa Therapeutics, Inc. | 61225M102 | Mar 2026 | 346,430 | $5.7M | 0.07% | EC |
| 141 | KalVista Pharmaceuticals, Inc. | 483497103 | Mar 2026 | 276,916 | $5.6M | 0.07% | EC |
| 142 | Janux Therapeutics, Inc. | 47103J105 | Mar 2026 | 392,349 | $5.5M | 0.07% | EC |
| 143 | Pharvaris NV | N/A | Mar 2026 | 191,961 | $5.4M | 0.07% | EC |
| 144 | MannKind Corp. | 56400P706 | Mar 2026 | 2,199,381 | $5.4M | 0.07% | EC |
| 145 | ORIC Pharmaceuticals, Inc. | 68622P109 | Mar 2026 | 424,422 | $5.4M | 0.07% | EC |
| 146 | Castle Biosciences, Inc. | 14843C105 | Mar 2026 | 215,689 | $5.3M | 0.07% | EC |
| 147 | Annexon, Inc. | 03589W102 | Mar 2026 | 952,884 | $5.3M | 0.06% | EC |
| 148 | UroGen Pharma Ltd. | N/A | Mar 2026 | 286,041 | $5.1M | 0.06% | EC |
| 149 | Kura Oncology, Inc. | 50127T109 | Mar 2026 | 628,449 | $5.1M | 0.06% | EC |
| 150 | Inhibrx Biosciences, Inc. | 45720N103 | Mar 2026 | 75,835 | $5.1M | 0.06% | EC |
| 151 | Stevanato Group SpA | N/A | Mar 2026 | 370,391 | $5.1M | 0.06% | EC |
| 152 | Arbutus Biopharma Corp. | 03879J100 | Mar 2026 | 1,119,437 | $5.0M | 0.06% | EC |
| 153 | Septerna, Inc. | 81734D104 | Mar 2026 | 200,845 | $4.8M | 0.06% | EC |
| 154 | Alto Neuroscience, Inc. | 02157Q109 | Mar 2026 | 212,677 | $4.8M | 0.06% | EC |
| 155 | Bicara Therapeutics, Inc. | 055477103 | Mar 2026 | 236,865 | $4.7M | 0.06% | EC |
| 156 | GH Research plc | N/A | Mar 2026 | 334,162 | $4.7M | 0.06% | EC |
| 157 | ArriVent Biopharma, Inc. | 04272N102 | Mar 2026 | 201,242 | $4.6M | 0.06% | EC |
| 158 | CytomX Therapeutics, Inc. | 23284F105 | Mar 2026 | 987,397 | $4.6M | 0.06% | EC |
| 159 | Cullinan Therapeutics, Inc. | 230031106 | Mar 2026 | 323,429 | $4.6M | 0.06% | EC |
| 160 | Replimune Group, Inc. | 76029N106 | Mar 2026 | 570,930 | $4.4M | 0.05% | EC |
| 161 | Precigen, Inc. | 74017N105 | Mar 2026 | 1,104,713 | $4.3M | 0.05% | EC |
| 162 | Arvinas, Inc. | 04335A105 | Mar 2026 | 403,100 | $4.3M | 0.05% | EC |
| 163 | Savara, Inc. | 805111101 | Mar 2026 | 775,563 | $4.2M | 0.05% | EC |
| 164 | Ironwood Pharmaceuticals, Inc. | 46333X108 | Mar 2026 | 1,173,471 | $4.1M | 0.05% | EC |
| 165 | Phathom Pharmaceuticals, Inc. | 71722W107 | Mar 2026 | 356,945 | $4.0M | 0.05% | EC |
| 166 | Zevra Therapeutics, Inc. | 488445206 | Mar 2026 | 413,742 | $3.9M | 0.05% | EC |
| 167 | Cytek Biosciences, Inc. | 23285D109 | Mar 2026 | 868,726 | $3.8M | 0.05% | EC |
| 168 | MeiraGTx Holdings plc | N/A | Mar 2026 | 430,643 | $3.7M | 0.05% | EC |
| 169 | ARS Pharmaceuticals, Inc. | 82835W108 | Mar 2026 | 463,404 | $3.7M | 0.05% | EC |
| 170 | BioAge Labs, Inc. | 09077V100 | Mar 2026 | 211,362 | $3.7M | 0.05% | EC |
| 171 | Sana Biotechnology, Inc. | 799566104 | Mar 2026 | 1,235,916 | $3.6M | 0.04% | EC |
| 172 | Rigel Pharmaceuticals, Inc. | 766559702 | Mar 2026 | 131,031 | $3.5M | 0.04% | EC |
| 173 | Zenas Biopharma, Inc. | 98937L105 | Mar 2026 | 175,941 | $3.4M | 0.04% | EC |
| 174 | Compass Pathways plc | 20451W101 | Mar 2026 | 612,150 | $3.4M | 0.04% | EC |
| 175 | Fulcrum Therapeutics, Inc. | 359616109 | Mar 2026 | 429,371 | $3.3M | 0.04% | EC |
| 176 | OPKO Health, Inc. | 68375N103 | Mar 2026 | 2,882,600 | $3.3M | 0.04% | EC |
| 177 | Solid Biosciences, Inc. | 83422E204 | Mar 2026 | 446,552 | $3.2M | 0.04% | EC |
| 178 | 4D Molecular Therapeutics, Inc. | 35104E100 | Mar 2026 | 338,744 | $3.2M | 0.04% | EC |
| 179 | Prothena Corp. plc | N/A | Mar 2026 | 323,349 | $3.1M | 0.04% | EC |
| 180 | Emergent BioSolutions, Inc. | 29089Q105 | Mar 2026 | 376,503 | $3.1M | 0.04% | EC |
| 181 | Myriad Genetics, Inc. | 62855J104 | Mar 2026 | 662,895 | $3.0M | 0.04% | EC |
| 182 | Absci Corp. | 00091E109 | Mar 2026 | 975,088 | $2.9M | 0.04% | EC |
| 183 | BridgeBio Oncology Therapeutics, Inc. | 107924102 | Mar 2026 | 324,513 | $2.9M | 0.04% | EC |
| 184 | Perspective Therapeutics, Inc. | 46489V302 | Mar 2026 | 693,460 | $2.9M | 0.04% | EC |
| 185 | Aclaris Therapeutics, Inc. | 00461U105 | Mar 2026 | 766,012 | $2.9M | 0.04% | EC |
| 186 | Altimmune, Inc. | 02155H200 | Mar 2026 | 926,610 | $2.9M | 0.04% | EC |
| 187 | Vanda Pharmaceuticals, Inc. | 921659108 | Mar 2026 | 405,038 | $2.8M | 0.03% | EC |
| 188 | Allogene Therapeutics, Inc. | 019770106 | Mar 2026 | 1,145,572 | $2.8M | 0.03% | EC |
| 189 | REGENXBIO, Inc. | 75901B107 | Mar 2026 | 331,423 | $2.8M | 0.03% | EC |
| 190 | Rocket Pharmaceuticals, Inc. | 77313F106 | Mar 2026 | 752,567 | $2.7M | 0.03% | EC |
| 191 | Pacific Biosciences of California, Inc. | 69404D108 | Mar 2026 | 2,021,533 | $2.7M | 0.03% | EC |
| 192 | Lexeo Therapeutics, Inc. | 52886X107 | Mar 2026 | 457,447 | $2.6M | 0.03% | EC |
| 193 | Alvotech SA | N/A | Mar 2026 | 763,481 | $2.6M | 0.03% | EC |
| 194 | Contineum Therapeutics, Inc. | 21217B100 | Mar 2026 | 200,362 | $2.6M | 0.03% | EC |
| 195 | Enanta Pharmaceuticals, Inc. | 29251M106 | Mar 2026 | 205,184 | $2.6M | 0.03% | EC |
| 196 | Lineage Cell Therapeutics, Inc. | 53566P109 | Mar 2026 | 1,621,430 | $2.6M | 0.03% | EC |
| 197 | Standard BioTools, Inc. | 34385P108 | Mar 2026 | 2,747,556 | $2.5M | 0.03% | EC |
| 198 | ADC Therapeutics SA | N/A | Mar 2026 | 673,142 | $2.5M | 0.03% | EC |
| 199 | Design Therapeutics, Inc. | 25056L103 | Mar 2026 | 235,859 | $2.5M | 0.03% | EC |
| 200 | Personalis, Inc. | 71535D106 | Mar 2026 | 393,153 | $2.5M | 0.03% | EC |
| 201 | Atea Pharmaceuticals, Inc. | 04683R106 | Mar 2026 | 460,056 | $2.5M | 0.03% | EC |
| 202 | Prime Medicine, Inc. | 74168J101 | Mar 2026 | 704,092 | $2.5M | 0.03% | EC |
| 203 | Keros Therapeutics, Inc. | 492327101 | Mar 2026 | 214,789 | $2.4M | 0.03% | EC |
| 204 | Fulgent Genetics, Inc. | 359664109 | Mar 2026 | 148,748 | $2.4M | 0.03% | EC |
| 205 | Tectonic Therapeutic, Inc. | 878972108 | Mar 2026 | 75,889 | $2.3M | 0.03% | EC |
| 206 | Aura Biosciences, Inc. | 05153U107 | Mar 2026 | 338,128 | $2.3M | 0.03% | EC |
| 207 | Kyverna Therapeutics, Inc. | 501976104 | Mar 2026 | 251,263 | $2.2M | 0.03% | EC |
| 208 | Maravai LifeSciences Holdings, Inc. | 56600D107 | Mar 2026 | 759,052 | $2.1M | 0.03% | EC |
| 209 | Immuneering Corp. | 45254E107 | Mar 2026 | 390,008 | $2.1M | 0.03% | EC |
| 210 | Anavex Life Sciences Corp. | 032797300 | Mar 2026 | 668,447 | $2.1M | 0.03% | EC |
| 211 | Entrada Therapeutics, Inc. | 29384C108 | Mar 2026 | 158,267 | $2.0M | 0.02% | EC |
| 212 | Ginkgo Bioworks Holdings, Inc. | 37611X209 | Mar 2026 | 317,323 | $1.9M | 0.02% | EC |
| 213 | Upstream Bio, Inc. | 91678A107 | Mar 2026 | 213,032 | $1.9M | 0.02% | EC |
| 214 | Neurogene, Inc. | 64135M105 | Mar 2026 | 94,694 | $1.9M | 0.02% | EC |
| 215 | LENZ Therapeutics, Inc. | 52635N103 | Mar 2026 | 206,971 | $1.9M | 0.02% | EC |
| 216 | Autolus Therapeutics plc | 05280R100 | Mar 2026 | 1,321,681 | $1.8M | 0.02% | EC |
| 217 | Editas Medicine, Inc. | 28106W103 | Mar 2026 | 731,163 | $1.8M | 0.02% | EC |
| 218 | Cabaletta Bio, Inc. | 12674W109 | Mar 2026 | 633,353 | $1.7M | 0.02% | EC |
| 219 | C4 Therapeutics, Inc. | 12529R107 | Mar 2026 | 608,839 | $1.6M | 0.02% | EC |
| 220 | Larimar Therapeutics, Inc. | 517125100 | Mar 2026 | 350,415 | $1.6M | 0.02% | EC |
| 221 | Candel Therapeutics, Inc. | 137404109 | Mar 2026 | 294,995 | $1.4M | 0.02% | EC |
| 222 | Arcturus Therapeutics Holdings, Inc. | 03969T109 | Mar 2026 | 186,967 | $1.4M | 0.02% | EC |
| 223 | OmniAb, Inc. | 68218J103 | Mar 2026 | 874,147 | $1.4M | 0.02% | EC |
| 224 | NovaBridge Biosciences | 44975P103 | Mar 2026 | 539,518 | $1.3M | 0.02% | EC |
| 225 | Voyager Therapeutics, Inc. | 92915B106 | Mar 2026 | 329,043 | $1.3M | 0.02% | EC |
| 226 | AC Immune SA | N/A | Mar 2026 | 443,438 | $1.2M | 0.02% | EC |
| 227 | Bicycle Therapeutics plc | 088786108 | Mar 2026 | 244,101 | $1.1M | 0.01% | EC |
| 228 | Caribou Biosciences, Inc. | 142038108 | Mar 2026 | 594,484 | $1.1M | 0.01% | EC |
| 229 | Codexis, Inc. | 192005106 | Mar 2026 | 683,417 | $1.1M | 0.01% | EC |
| 230 | Lyell Immunopharma, Inc. | 55083R203 | Mar 2026 | 54,413 | $1.1M | 0.01% | EC |
| 231 | Cellectis SA | 15117K103 | Mar 2026 | 339,873 | $1.1M | 0.01% | EC |
| 232 | Foghorn Therapeutics, Inc. | 344174107 | Mar 2026 | 223,190 | $1.1M | 0.01% | EC |
| 233 | Quanterix Corp. | 74766Q101 | Mar 2026 | 284,827 | $1.0M | 0.01% | EC |
| 234 | Sagimet Biosciences, Inc. | 786700104 | Mar 2026 | 189,187 | $989K | 0.01% | EC |
| 235 | Quantum-Si, Inc. | 74765K105 | Mar 2026 | 1,223,534 | $947K | 0.01% | EC |
| 236 | Silence Therapeutics plc | 82686Q101 | Mar 2026 | 173,313 | $913K | 0.01% | EC |
| 237 | Tenaya Therapeutics, Inc. | 87990A106 | Mar 2026 | 1,200,002 | $831K | 0.01% | EC |
| 238 | Neumora Therapeutics, Inc. | 640979100 | Mar 2026 | 421,430 | $822K | 0.01% | EC |
| 239 | PepGen, Inc. | 713317105 | Mar 2026 | 451,333 | $799K | 0.01% | EC |
| 240 | Humacyte, Inc. | 44486Q103 | Mar 2026 | 1,222,120 | $741K | 0.01% | EC |
| 241 | Black Diamond Therapeutics, Inc. | 09203E105 | Mar 2026 | 321,542 | $685K | 0.01% | EC |
| 242 | Pyxis Oncology, Inc. | 747324101 | Mar 2026 | 345,130 | $504K | 0.01% | EC |
| 243 | Gossamer Bio, Inc. | 38341P102 | Mar 2026 | 1,510,536 | $496K | 0.01% | EC |
| 244 | Jyong Biotech Ltd. | N/A | Mar 2026 | 206,499 | $444K | 0.01% | EC |
| 245 | Akero Therapeutics, Inc. | 009CVR044 | Mar 2026 | 515,954 | $341K | 0.00% | — |
| 246 | Aardvark Therapeutics, Inc. | 002942100 | Mar 2026 | 89,682 | $338K | 0.00% | EC |
| 247 | Immutep Ltd. | 45257L108 | Mar 2026 | 809,244 | $284K | 0.00% | EC |
| 248 | Alpha Teknova, Inc. | 02080L102 | Mar 2026 | 79,636 | $230K | 0.00% | EC |
| 249 | N/A | N/A | Mar 2026 | 33 | $56K | 0.00% | DE |
| 250 | Contra Chinook Therape | 169CVR016 | Mar 2026 | 320,962 | $55K | 0.00% | — |
| 251 | Cartesian Therapeutics, Inc. | 816212112 | Mar 2026 | 6,098 | $2K | 0.00% | — |
| 252 | Fusion Pharmaceuticals, Inc. | 361CVR012 | Mar 2026 | 1,880 | $1K | 0.00% | — |
| 253 | Cargo Therapeutics, Inc. | 141CVR019 | Mar 2026 | 198,104 | $2 | 0.00% | — |
| 254 | Akouos, Inc. | 009CVR036 | Mar 2026 | 157,087 | $2 | 0.00% | — |
| 255 | Third Harmonic Bio, Inc. | 88427A107 | Mar 2026 | 134,478 | $1 | 0.00% | EC |
| 256 | OmniAb, Inc. | 68218J301 | Mar 2026 | 46,839 | $0 | 0.00% | — |
| 257 | OmniAb Operations, Inc. | 68218J202 | Mar 2026 | 46,839 | $0 | 0.00% | — |
| 258 | N/A | N/A | Mar 2026 | 53 | $-73747 | -0.00% | DE |